INTRODUCTION

The Diabetes Control and Complications Trial (DCCT) demonstrates that tight glycemic control has long-term beneficial effects on the risks of microvascular complications and cardiovascular disease in patients with Type 1 diabetes (1, 2). Accordingly, multiple-injection insulin regimens combining intermediate-acting insulin, such as NPH insulin, with mealtime bolus insulin, such as regular insulin, have been used conventionally for the treatment of Type 1 diabetes.
These regimens have yielded improved glycemic control with a lower incidence of hypoglycemia. Insulin glargine is a long-acting, basal insulin analog, which has a smoother time-concentration profile as compared to NPH insulin, with a duration of action of about 24 h (3). Clinical trials of insulin glargine for Type 1 diabetes in many countries including Japan have revealed that treatment with this insulin is associated with a reduced frequency of severe hypoglycemia while being at least as effective as NPH insulin therapy in maintaining glycemic control (4-7). The goals of the present retrospective study were to examine 1) whether treatment with an insulin glargine-based regimen would be associated with a reduced frequency of nocturnal hypoglycemia and episodes of hypoglycemia with unconsciousness as compared with treatment with an NPHbased regimen, 2) whether a once-daily insulin glarginebased regimen would be sufficient in the clinical
T a b l e 1 . Hb A1 c Va l u e s a f t e r S wi t c h i n g t o Gl a r g i n e T h e r a p y -Ca t e g o r i z e d b y t h e T y p e o f Me a l t i me I n s u l i n i n t h e P a t i e n t s insulin glargine-based regimen no longer suffered from these episodes after initiation of the insulin glargine-based regi
T a b l e 2 . Gl y c e mi c Co n t r o l Ca t e g o r y a f t e r T r e a t me n t wi t h I n s u l i n Gl a r g i n e i n Co m p a r i s o n wi t h t h a t a t B a s e l i n e
T a b l e 3 . I n j e c t i o n S c h e d u l e o f B a s a l I n s u l i n i n t h e P a t i e n t s b e f o r e ( wi t h NP H i n s u l i n ) a n d 1 2 Mo n t h s a f t e r t h e T r e a t me n t S wi t c h t o I n s u l i n Gl a r g i n e some diabetic patients receiving insulin glargine, it is necessary to use twice-daily injections to obtain reasonable glycemic control (12) .
F i g u r e . Co r r e l a t i o n b e t we e n t h e r a t i o o f t h e d a i l y d o s e o f b a s a l i n s u l i n t o t h a t o f t o t a l i n s u l i n ( b as a l / t o t a l i n s u l i n r a t i o ) a n d t h e b o d y ma s s i n d e x i n 7 5 p a t i e n t s r e c e i v i n g o n c e -d a i l y i n s u l i n g l a r g i n e wi t h me a l t i me i n s u l i n i n j e c t i o n s . T h e r e wa s a we a k c o r r e l a t i o n b e t we e n t h e b a s a l / t o t a l i n s u l i n r at i o a n d t h e b o d y ma s s i n d e x i n t h e 7 5 p a t i e n t s r
The average ratio of the daily dose of insulin glargine to that of the total insulin noted at the end of the 12-months after the switch to a glargine-based regimen in this study ( (8) , as in our present cohort and in other reports from Japan (6, 7, 9) . This value is lower than the value reported for Type 1 diabetes patients from other countries (4, 5, 13 (14) , while the fat content of the diet is correlated with the insulin resistance in patients with Type 1 diabetes (13) .
